MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate.
A Media Snippet accompanying this announcement is available by clicking on the image or link below:
Incannex Contact Information:
Incannex Healthcare Limited
Mr Joel Latham
Managing Director and Chief Executive Officer
+61 409 840 786
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations Contact – United States
Alyssa Factor
Edison Group
+1 (860) 573 9637
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.00 |
| Daily Change: | 0.03 1.52 |
| Daily Volume: | 8,317 |
| Market Cap: | US$35.280M |
November 14, 2024 September 30, 2024 | |
UGE International develops, owns, and operates commercial and community solar projects in the United States and strategic markets abroad. Our distributed energy solutions deliver cheaper, cleaner energy to businesses and consumers...
CLICK TO LEARN MORE
Leveraging its vertically-integrated approach from mine to material manufacturing, Graphite One intends to produce high-grade anode material for the lithium-ion electric vehicle battery market and energy storage systems...
CLICK TO LEARN MORE
